130933-88-9

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 
• 3153-36-4 4-chloro-butyric acid ethyl ester 

Downstream Products

• 130933-46-9 4-<4-(4-fluorophenyl)-1-piperazinyl>butyric acid 
• 130933-83-4 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-((4aR,5R,11aR)-7-methoxy-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-butyramide 
• 130953-92-3 N-((4aR,5R,11aR)-7-Chloro-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-butyramide 
• 130933-79-8 N-((4aR,5R,11aR)-7-Fluoro-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-butyramide 
• 130933-81-2 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-((4aR,5R,11aR)-7-methyl-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-butyramide 
• 130982-73-9 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aR,5S,11aS)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 130933-61-8 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aR,5S,11aR)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 130933-61-8 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aS,5S,11aS)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 131063-06-4 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aS,5S,11aR)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 130933-86-7 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(6aS,10aS,11S)-6,6a,7,8,9,10,10a,11-octahydro-dibenzo[b,e]oxepin-11-yl-butyramide 
• 130933-85-6 (6aR^*,10aR^*,11R^*)-11-<<4-<4-(4-fluorophenyl)-1-piperazinyl>butyryl>amino>-6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin 5-oxide 

Relevant academic research and scientific papers

Solventless microwave assisted protocol for synthesis of arylalkylpiperazines using Cs-base

A series of some arylalkylpiperazines was prepared in good yields under microwave irradiation in dry media conditions using CsOH with high chemo- and regioselectivity.

Novel quinazolinone derivatives as 5-HT7 receptor ligands

5-HT7 receptor antagonists generated antidepressant-like effects in animal model and the involvement of the 5-HT7 receptor in other pathophysiological mechanisms such as thermoregulation, learning and memory, and sleep has been highl

Fused heterocyclic compounds and pharmaceutical applications thereof

The present invention relates to a fused heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, and a medicament containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound of the present invention is a useful antipsychotic agent effective not only for positive symptoms centering on hallucination and delusion characteristic of the acute stage of schizophrenia, but also negative symptoms of apathy, abulia and autism. The inventive compound is expected to make a highly safe antipsychotic agent associated with less side effects, such as extrapyramidal symptoms and endocrine disturbance, which are observed when a conventional antipsychotic agent having a D2receptor blocking action is administered. Therefore, the inventive compound can be used as a therapeutic agent for the diseases such as schizophrenia.

A New Class of Calcium Antagonists. Synthesis and Biological Activity of 11--6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin Derivatives

A series of 11--6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin derivatives were prepared and found to be structurally new class of calcium antagonists.The structure-activivty relationship studies indicated that the optimum was (6aR*,10aR*,11R*)-11-butyryl>amino>-6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin (31, pA2 8.16), which was superior to diltiazem (pA2 7.42) in calcium antagonistic activity.Compound 31 showed antihypertensive activity in anesthetized rats, without a significant effect on the heart rate.It had also antianginal effects in vasopressin-induced ST-elevation testings in rats.These potencies of 31 were essentially equal to those of diltiazem.